Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451893 | 0.86 | ADAM17 (0.52) | ATML3MBTL1ADAM17 | |
| SCHEMBL5077366 | 0.86 | ADAM17 (0.52) | ATML3MBTL1ADAM17 | |
| SCHEMBL11076157 | 0.82 | ADAM17 (0.79) | ADAM17 | |
| SCHEMBL28065194 | 0.81 | ATM (0.58) | ATML3MBTL1MAOBMAOACNR2 | |
| SCHEMBL11470653 | 0.81 | ADAM17 (0.42) | ADAM17 | |
| SCHEMBL11078762 | 0.81 | ADAM17 (0.47) | ADAM17 | |
| SCHEMBL11074900 | 0.80 | ADAM17 (0.54) | ATML3MBTL1ADAM17 | |
| SCHEMBL11911737 | 0.79 | ATM (0.61) | ATML3MBTL1MAOBMAOACNR2 | |
| SCHEMBL11075435 | 0.79 | ADAM17 (0.49) | ATML3MBTL1ADAM17 | |
| SCHEMBL3984092 | 0.78 | ADAM17 (0.53) | ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110177551-B | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-7875643-B2 | (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia | GLAXO GROUP LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7855298-B2 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1891057-B1 | AZABICYCLO[3.1.0]HEXANE DERIVAIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-7803820-B2 | 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| EP-1891057-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2006133946-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326011-A1 | AZAB I CYCLO [3 . 1 . 0] HEXANE DERIVATIVES AS DOPAMIN D3 RECEPTOR MODULATORS | CHRNB3, DRD2, DRD3 | ATM 4823/4885L3MBTL1 3528/4885ADAM17 3330/4885 |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | ATM 4612/4885L3MBTL1 1374/4885ADAM17 4579/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | ATM 4515/4885L3MBTL1 1780/4885ADAM17 4446/4885 |
| US-20080167357-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful as Modulators of Dopamine D3 Receptors | HTR5A, DRD3, HTR3C | ATM 4093/4885L3MBTL1 2439/4885ADAM17 4432/4885 |
| US-20080176917-A1 | 3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands | DRD3, HTR3C, HTR5A | ATM 3858/4885L3MBTL1 1686/4885ADAM17 4420/4885 |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | ATM 4515/4885L3MBTL1 1780/4885ADAM17 4446/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | ATM 3139/4885L3MBTL1 1288/4885ADAM17 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.